Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

NCT ID: NCT06518551

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-01
• Study Completion Date: 2034-12-31

Brief Summary

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.

The names of the study drugs involved in this study are:

• Iberdomide (a type of cereblon E3 ligase modulator)
• Elotuzumab (a type of monoclonal antibody)
• Dexamethasone (a type of steroid)

Detailed Description

This is a phase I/II, open-label, non-randomized, single-stage study to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. Iberdomide has demonstrated some antitumor activity in laboratory studies.

The U.S. Food and Drug Administration (FDA) has approved Elotuzumab as a treatment option for Multiple Myeloma. Dexamethasone, also FDA approved, is a type of steroid and is usually combined with other chemotherapy for the treatment of blood cancers, such as myeloma and leukemias. The U.S. Food and Drug Administration (FDA) has not approved Iberdomide as a treatment for Multiple Myeloma.

The research study procedures include screening for eligibility, study treatment visits, bone marrow biopsies, blood and urine tests, electrocardiograms (ECGs), X-rays, and Positron Emission Tomography (PET) scans, Computerized Tomography (CT) scans, or Magnetic Resonance Imaging (MRI) scans.

It is expected about 49 people will take part in this research study.

Bristol-Myers Squibb and Celgene, a BMS company, are supporting this research study by providing study drug and providing funding for the trial.

Conditions

Myeloma; Multiple Myeloma; Refractory Multiple Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1: Dose Escalation

Participants will be enrolled in a standard 3+3 dose escalation design to find the Maximum Tolerated Dose (MTD) of Iberdomide, starting at Dose Level 0 and increasing to Dose Level 1

• Baseline visit
• Cycle 1 through Cycle 2:

• Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily
• Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily
• Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Elotuzumab 1x daily
• Cycle 3 through End of Treatment:

• Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily
• Day 1 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily
• Day 1 of 28 Day Cycle: Predetermined dose of Elotuzumab 1x daily
• End of Treatment visit
• 14 Day Follow Up Visit: to be in-clinic after end of treatment visit
• Follow Up: Every 28 days for up to 2 years
• Dose expansion will proceed according to dose-limiting toxicity (DLT) guidelines per the protocol

Group Type: EXPERIMENTAL

Elotuzumab

Intervention Type: DRUG

Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.

Iberdomide

Intervention Type: DRUG

A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.

Dexamethasone

Intervention Type: DRUG

Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.

Phase 2: Dose Expansion

Participants will be enrolled and will complete study procedures as follows:

• Baseline visit
• Cycle 1 through Cycle 2:

• Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily.
• Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily.
• Days 1, 8, 15, and 22 of 23 Day Cycle: Predetermined dose of Elotuzumab 1x daily.
• Cycle 3 through End of Treatment:

• Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily.
• Day 1 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily.
• Days 1, 8, 15, and 22 of 23 Day Cycle: Predetermined dose of Elotuzumab 1x daily.
• End of Treatment visit
• 14 Day Follow Up Visit: to be in-clinic after end of treatment visit.
• Follow Up: Every 28 days for up to 2 years

Group Type: EXPERIMENTAL

Elotuzumab

Intervention Type: DRUG

Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.

Iberdomide

Intervention Type: DRUG

A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.

Dexamethasone

Intervention Type: DRUG

Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.

Interventions

Elotuzumab

Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.

Intervention Type: DRUG

Iberdomide

A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.

Intervention Type: DRUG

Dexamethasone

Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.

Intervention Type: DRUG

Other Intervention Names

BMS-901608; CC-220; Iberdomide hydrochloride; C25H28N3O5Cl; BMS-986382; Decadron; 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione

Eligibility Criteria

Inclusion Criteria

• Previously diagnosed with MM based on standard IMWG criteria
• Patient has given voluntary written informed consent before any study-related procedures not part of normal medical care are performed, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
• Patient who has been treated with at least 4 prior lines of anti-myeloma treatment including immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
• In addition, to at least 4 prior lines of anti-myeloma treatment, patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion
• ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
• Screening Laboratory evaluations within the following parameters

• Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used more recently than 7 days prior to initiation of therapy)
• Platelet count ≥ 75,000 cells/dL (75 x 109/L) (without transfusions during the 7 days prior to initiation of therapy)
• Hemoglobin ≥ 8.0 g/dL (RBC transfusions are permitted)
• Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
• AST or ALT ≤ 3x ULN
• Creatinine clearance ≥ 30 ml/min according to the Cockroft-Gault formula:

• Female CrCl = [(140 - age in years) x weight in kg x 0.85] / [72 x serum creatinine in mg/dL]
• Male CrCl = [(140 - age in years) x weight in kg x 1.00] / [72 x serum creatinine in mg/dL]
• Age ≥18 years.
• Ability to understand and the willingness to sign a written informed consent document.
• A Female of childbearing potential (FCBP) must:

• Have two negative pregnancy tests before enrollment and randomization into the clinical studies and prior to each re-supply of study drug during the clinical studies based on the frequency outlined in the Pregnancy Prevention Plan (PPP, Appendix D).
• Sexually active FCBP must agree to use protocol-specified contraceptive methods during participation in the clinical studies and for at least 28 days after the last dose of study drug.
• Sexually active males (including those who have had a vasectomy) must agree to use protocol specified contraceptive methods during participation in the clinical studies and for at least 28 days after the last dose of study drug.
• All participants (male and female with or without childbearing potential) must agree to abstain from donating blood products for at least 28 days after the last dose of study drug and semen or sperm while taking study drug and for at least 28 days after the last dose of study drug.

Exclusion Criteria

• Prior exposure to Iberdomide
• Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
• Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy
• Known central nervous system involvement.
• Systemic treatment, within 14 days before the first dose of treatment, with strong CYP3A or inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort OR systemic treatment within 14 days of the first dose of treatment with a strong inhibitor of CYP1A2 (ciprofloxacin, fluvoxamine, cimetidine, enoxacin, ethynyl estradiol, mexiletine)
• Any medical or psychiatric illness/social situation that in the Investigator's opinion, would impose excessive risk to the patient, would adversely affect his/her participating in this study or would limit compliance with study requirements.
• Currently active graft versus host disease of any stage or grade after allogeneic stem cell transplantation
• Prior major surgical procedure or radiation therapy within 14 days of initiation of therapy.

• Those who require a limited course of radiation for management of bone pain more than 14 days out from initiation of therapy are not excluded
• Any active, or uncontrolled cardiovascular conditions, including but not limited to uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, grade 3 thromboembolic event or myocardial infarction within the past 6 months.
• The following therapies within the stated time frames prior to initiation of therapy:

• Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 21 days (42 days for nitrosoureas).
• The use of live vaccines within 30 days.
• IMiDs or proteasome inhibitors within 14 days.
• Other investigational therapies and/or monoclonal antibodies within 4 weeks.
• Prior peripheral stem cell transplant within 12 weeks.
• Prior allogeneic stem cell transplantation with active graft-versus-host-disease.
• Those who require a limited course of daily requirement for corticosteroids (equivalent to >10 mg/day prednisone, though >10mg/day is acceptable if physiological levels require, so long as the dose is stable for at least 7 days prior to initiation of therapy. Inhalation corticosteroids are exempt from this criterion.

• Lower amounts of corticosteroids that are not part of a daily requirement within 14 days prior to initiating therapy
• Concurrent symptomatic amyloidosis or plasma cell leukemia
• POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)
• Infection requiring systemic antibiotic therapy or other serious infection within 7 days of starting therapy.

• Those who are on prophylactic antibiotics only, or on antibiotics and have confirmation of resolution of active infection are eligible.
• Known seropositive for active viral infection with human immunodeficiency virus (HIV) hepatitis B (HBV) or hepatitis C viral (HCV). Those who are seropositive because of hepatitis B vaccine are eligible. Patients who are positive for HBV core antibody or HBV surface antigen must have a negative polymerase chain reaction (PCR) result prior to enrollment. Those who are PCR positive will be excluded
• Female patients who are pregnant or lactating.
• Participants who are receiving any other investigational agents for any indication
• History of erythema multiforme or severe hypersensitivity to prior IMiD's® or those who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
• Inability to tolerate thromboprophylaxis
• Failure to have fully recovered (≤ Grade 2 according to CTCAE v 5) from the reversible effects of prior chemotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Omar Nadeem, MD

OTHER

Sponsor Role: lead

Responsible Party

Omar Nadeem, MD

Sponsor Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Omar Nadeem, MD

Role: PRINCIPAL_INVESTIGATOR

Dana-Farber Cancer Institute

Locations

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status: NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status: RECRUITING

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Omar Nadeem, MD

Role: CONTACT

Omar_Nadeem@dfci.harvard.edu

617-632-4703

Facility Contacts

Omar Nadeem, MD

Role: primary

Omar_Nadeem@dfci.harvard.edu

617-632-4703

David Avigan, MD

Role: primary

davigan@bidmc.harvard.edu

617-667-9920

Omar Nadeem, MD

Role: primary

Omar_Nadeem@dfci.harvard.edu

617-632-4703

Other Identifiers

24-189

Identifier Type: -

Identifier Source: org_study_id